menu
    • menu
    [{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Arena Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"RIST4721","moa":"CXCR-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Arena Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Arena Pharmaceuticals"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"RIST4721","moa":"CXCR-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Aristea Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"RIST4721","moa":"CXCR-2 receptor","graph1":"Dermatology","graph2":"Phase II","graph3":"Aristea Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Aristea Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aristea Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for RIST4721

    Menu

    RIST4721

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aristea Therapeutics Announces Discontinuation of RIST4721 Development Program and Decision to Dissolve the Co...

                            Details : RIST4721, is a solid oral dose that inhibits the activity of CXCR2. CXCR2 is a prominent cytokine receptor with an important role in the recruitment of neutrophils to the site of inflammation.

                            Product Name : RIST4721

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Arena Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aristea Therapeutics Announces Dosing of First Patient in Phase 2a Trial of RIST4721 in Hidradenitis Suppurati...

                            Details : The phase 2a study represents the second disease under investigation for the CXCR2 antagonist, RIST4721 and its initiation brings one step closer to potentially developing a treatment for HS.

                            Product Name : RIST4721

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 30, 2022

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Arena Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aristea Therapeutics Announces Dosing of First Patient in Open-Label Extension for Phase 2b Trial of RIST4721 ...

                            Details : RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases.

                            Product Name : RIST4721

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 30, 2022

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Aristea Therapeutics Announces Dosing of First Patient in Phase 2b Trial of RIST4721 in Palmoplantar Pustulosi...

                            Details : Aristea has Phase 2a studies in development for RIST4721 in four additional CXCR2-mediated diseases: familial Mediterranean fever, Behcet's disease, hidradenitis suppurativa, and inflammatory bowel disease.

                            Product Name : RIST4721

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2022

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Arena Pharmaceuticals

                            Deal Size : $70.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arena Pharmaceuticals and Aristea Therapeutics Establish Collaboration

                            Details : RIST4721 is an oral CXCR2 antagonist being developed for the treatment of PPP with results reported from its Phase 2a clinical trial in 2020. Agreement Provides Arena with Exclusive Option to Acquire Aristea and its CXCR2 Programs post-Phase 2.

                            Product Name : RIST4721

                            Product Type : Other Small Molecule

                            Upfront Cash : $60.0 million

                            July 27, 2021

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Arena Pharmaceuticals

                            Deal Size : $70.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed

                            Aristea Therapeutics

                            U.S.A arrow
                            HPAPI Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Study Phase : Phase II

                            Sponsor : Fidelity Management & Research Company

                            Deal Size : $63.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Aristea Completes $63 Million Series B Financing to Accelerate Clinical Development of Novel Immunotherapy Dru...

                            Details : Aristea will use the proceeds of the financing to continue the build-out of its leadership team, the formation of new partnerships and the advancement of the development of its portfolio including RIST4721, programs to address orphan diseases.

                            Product Name : RIST4721

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            July 27, 2021

                            Lead Product(s) : RIST4721

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase II

                            Sponsor : Fidelity Management & Research Company

                            Deal Size : $63.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth